Compare Nasdaq100 ETF (QQQ) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nasdaq100 ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? Nasdaq100 ETF trades at $750.56 (market cap $506.92B), while Vertex Pharmaceuticals Incorporated trades at $510.77 (market cap $127.55B). The key difference: Nasdaq100 ETF is far larger — about 4× Vertex Pharmaceuticals Incorporated's market cap, and Nasdaq100 ETF is trading nearer its 52-week high, Vertex Pharmaceuticals Incorporated nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nasdaq100 ETF for 162 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| QQQ | VRTX | |
|---|---|---|
Market Cap | $506.92B | $127.55B |
Volume | 48,326,518 | 1,487,944 |
52-Week High | $759.66 | $557.96 |
52-Week Low | $558.34 | $407.37 |
Typical Hold Time | 162 Days | 120 Days |
Sector | — | Health |
Enterprise Value | — | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QQQ trades at $749.24, down 1.12% with a bullish technical signal from moving averages. The ETF shows neutral oscillator readings and mixed analyst sentiment with a 50% buy/50% sell split. Recent news highlights QQQ's tech concentration and fee comparisons with competing ETFs, while broader market concerns about AI valuations and interest rates create headwinds.
The outlook remains cautiously optimistic given strong technical momentum, though elevated tech valuations and Federal Reserve policy pose risks. QQQ's innovation-focused portfolio offers growth exposure but requires monitoring of concentration risk in the technology sector amid market volatility.
Vertex Pharmaceuticals (VRTX) trades at $509.98, up 0.86% today, with a bearish technical signal but strong fundamentals. The company reported $12.00B revenue in 2025 with a 35% net income margin and robust cash flow. Recent positive Phase 2b data for inaxaplin in kidney disease and dominant cystic fibrosis market position support growth. Analysts maintain a strong buy consensus with a $573.50 price target, indicating 12% upside potential.
Outlook remains positive driven by pipeline expansion and high profitability, though risks include clinical trial outcomes and market volatility. The stock's valuation at 29.31 P/E is reasonable for its growth profile, but investor sentiment is cautious near-term due to mixed earnings beats and technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Nasdaq100 ETF
The ETF is designed to track the performance of the securities and the stocks in the NASDAQ-100 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on QQQ →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
